Effects of dihydroxy gymnemic triacetate (DGT) on expression of apoptosis associated proteins in human prostate cancer cell lines (PC3)

References

• Thun MJ, De Lancey JO, Center MM, et al. The global burden of cancer: priorities for prevention. Carcinogenesis 2010;31:100–10
   PubMed Web of Science ®Google Scholar
• Pramanik KC, Pandey AK. Natural compounds: prospective of chemoprevention. Endocrinol Metab Synd 2013;2:e115
   Google Scholar
• Da Rocha BA, Lopes RM, Schwartsmann G. Natural products in anticancer therapy. Curr Opin Pharmacol 2001;1:364–9
   PubMedGoogle Scholar
• Nair R, Withington J, Ghos S, Henderson A. Early detection and patient risk stratification in prostate cancer. In: Ashutosh tewari, ed. Prostate cancer: a comprehensive perspective. London, Heidelberg, New York, Dordrecht: Springer; 2013:34–45
   Google Scholar
• Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427–33
   PubMed Web of Science ®Google Scholar
• Brawer MK. Hormonal therapy for prostate cancer. Rev Urol 2006;8:S1–9
   PubMedGoogle Scholar
• Isaacs JT, Lundmo PI, Berges R, et al. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 1992;13:457–64
   PubMed Web of Science ®Google Scholar
• Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important. BMJ 2001;322:1536–8
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70
   PubMed Web of Science ®Google Scholar
• Khan KH, Blanco-Codessido M, Molife LR. Cancer therapeutics: targetting the apoptotic pathway. Crit Rev Oncol Hematol 2014;90:200–19
   PubMed Web of Science ®Google Scholar
• Cryns V, Yuan J. Proteases to die for. Genes Dev 1998;12:1551–70
   PubMed Web of Science ®Google Scholar
• Raffo AJ, Perlman H, Chen M-W, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438–45
   PubMed Web of Science ®Google Scholar
• Daisy P, Eliza J, Majeed Mohamed Farook KA. A novel dihydroxy gymnemic triacetate isolated from Gymnema sylvestre possessing normoglycemic and hypolipidemic activity on STZ-induced diabetic rats. J Ethnopharmacol 2009;126:339–44
   PubMed Web of Science ®Google Scholar
• Mhasker KS, Caius JF. A study of Indian medicinal plants. II. Gymnema sylvestre R.Br. Indian J Med Res 1930;16:2–75
   Google Scholar
• Alley MC, Scudiero DA, Monks A, et al. Feasibility of drugs screening with panels of human tumor cell lines using a microculturetetrazolium assay. Cancer Res 1988;48:589–601
   PubMed Web of Science ®Google Scholar
• Takada M, Noguchi A, Sayama Y, et al. Inositol 1,4,5-trisphosphate receptor-mediated initial Ca2 mobilization constitutes a triggering signal for hydrogen peroxide-induced apoptosis in INS-1-cells. Biol Pharm Bull 2011;34:954–8
   PubMed Web of Science ®Google Scholar
• Thylur RP, Senthivinayagam S, Campbell EM, et al. Mixed lineage kinase 3 modulates β-catenin signaling in cancer cells. J Biol Chem 2011;286:37470–82
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:256–75
   Web of Science ®Google Scholar
• Zielinski RR, Eigl BJ, Chi KN. Targeting the apoptosis pathway in prostate cancer. Cancer J 2013;19:79–89
   PubMed Web of Science ®Google Scholar
• Khanna VG, Kannabiran K. Anticancer-cytotoxic activity of saponins isolated from the leaves of Gymnema sylvestre and Eclipta prostrata on HeLa cells. Int J Green Pharm 2009;3:227–9
   Google Scholar
• Chakraborty D, Ghosh S, Bishayee K, et al. Antihyperglycemic drug Gymnema sylvestre also shows anticancer potentials in human melanoma A375 cells via reactive oxygen species generation and mitochondria-dependent caspase pathway. Integr Cancer Ther 2013;12:433–41
   PubMed Web of Science ®Google Scholar
• Srikanth AV, Maricar S, Lakshmi Narsu M, et al. Anticancer activity of Gymnema sylvestre R.B. Int J Pharm Sci Nanotechnol 2010;3:897–9
   Google Scholar
• Martikainen P, Kyproanou N, Issac J. Programmed death of non proliferating androgen independent prostatic cancer cells. Cancer Res 2009;51:4693–700
   Google Scholar
• Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266:1821–8
   PubMed Web of Science ®Google Scholar
• Vermeulen K, Berneman ZN, Van Bockstaele DR. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131–49
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803–15
   PubMed Web of Science ®Google Scholar
• Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008;98:523–8
   PubMed Web of Science ®Google Scholar
• Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005;106:408–18
   PubMed Web of Science ®Google Scholar
• Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ 2005;12:942–61
   PubMed Web of Science ®Google Scholar
• Van Loo G, Saelens X, Matthijssens F, et al. Caspases are not localized in mitochondria during life or death. Cell Death Differ 2002;9:1207–11
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178–94
   PubMed Web of Science ®Google Scholar